terbutaline

Trade name: bricanyl

Small moleculeapproved

Approved

Mar 25, 1974

Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation. The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Terbutaline is used for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial. — NCATS

Clinical trial activity

40 trials · 33 clinical orgs · 17 marketing orgs

Phase 1
2
Phase 2
19
Phase 3
17
Phase 4
7

Earliest trial started Sep 1, 2002 (NCT00802230)

Timeline

1970s

  1. Mar 25, 1974

    Sanofi-Aventis — Earliest FDA Approval

  2. Mar 25, 1974

    Sanofi-Aventis — NDA Secondary Org

  3. Mar 25, 1974

    Sanofi-Aventis — NDA Organization

  4. May 17, 1976

    Ani Pharmaceuticals — NDA Secondary Org

  5. May 17, 1976

    Ani Pharmaceuticals — Marketing Organization

1980s

  1. Nov 30, 1981

    Pharmacare PLC, Palestine — NDA Secondary Org

2000s

  1. Jun 26, 2001

    Impax Laboratories — Marketing Organization

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  3. Apr 23, 2004

    Athenex, Inc. — Marketing Organization

  4. Apr 23, 2004

    Chartwell Pharmaceuticals — Marketing Organization

  5. May 26, 2004

    Fresenius — Marketing Organization

  6. Jul 20, 2004

    Teva — Marketing Organization

  7. Jul 20, 2004

    Dr. Reddy's Laboratories — Marketing Organization

  8. Mar 25, 2005

    Lannett Company, Inc. — Marketing Organization

  9. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  10. Jan 7, 2008

    Akorn, Inc. — Marketing Organization

  11. Jan 7, 2008

    Epic Pharma Llc — Marketing Organization

  12. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

  13. May 20, 2009

    Hikma — Marketing Organization

2010s

  1. Nov 8, 2013

    United Biomedical — Marketing Organization

  2. Nov 8, 2013

    Areva Med LLC — Marketing Organization

2020s

  1. Jun 19, 2020

    TWi Biotechnology, Inc. — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewMar 25, 1974

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O
Mol. weight
548.66 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

  • brethaire
  • brethaire
  • brethine
  • brethine
  • brican
  • bricanyl
  • bricanyl
  • bricanyl
  • bricanyl
  • bricanyl sa
  • bricanyl sa
  • bricaril
  • kwd-2019
  • kwd-2019
  • monovent
  • monovent
  • monovent sa
  • terbasmin
  • terbasmin
  • terbutalin
  • terbutalin
  • terbutalin
  • terbutalin
  • terbutalina
  • terbutalina
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline
  • terbutaline hemisulfate
  • terbutaline hemisulfate
  • terbutaline sulfate
  • terbutaline sulfate
  • terbutaline sulfate
  • terbutaline sulfate
  • terbutaline (sulfate de)
  • terbutaline (sulfate de)
  • terbutaline sulphate
  • terbutaline sulphate
  • terbutaline sulphate
  • terbutalini sulfas
  • terbutalini sulfas
  • terbutalinsulfat
  • terbutalinum
  • terbutalinum

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06626620Phase 3Jan 1, 2024Nishtar Medical University, RESnTEC, Institute of Research
NCT05494307Phase 2Sep 1, 2022Peking University
NCT04973345Phase 2/Phase 3 (Phase 3)Mar 31, 2022Duke University, The EMMES Corporation
NCT05193968N/AFeb 24, 2022Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
NCT04705727Phase 3Apr 12, 2021AstraZeneca, Centre Hospitalier Intercommunal Creteil
NCT04481282Phase 2Jul 8, 2020Peking University
NCT03565302N/AJun 25, 2018University of Copenhagen
NCT05326269N/AApr 23, 2017Hospital Kemaman
NCT03106753Phase 4Apr 12, 2017Icahn School of Medicine at Mount Sinai
NCT04468568N/AJan 8, 2017University of Sao Paulo
NCT02712658N/ASep 1, 2015University of Copenhagen
NCT02557581N/AJul 1, 2015University of Copenhagen
NCT02322788Phase 3Mar 1, 2015AstraZeneca
NCT02224157Phase 3Nov 28, 2014AstraZeneca
NCT02178059Phase 1Aug 1, 2014AstraZeneca, IQVIA
NCT02149199Phase 3Jul 7, 2014AstraZeneca
NCT02115256Phase 2/Phase 3 (Phase 3)Jul 1, 2014Icahn School of Medicine at Mount Sinai
NCT01944033Phase 3Jul 1, 2013University of Monastir
NCT01651962Phase 4Aug 1, 2012University of Arizona
NCT02103374Phase 4Jan 1, 2012University of Toulouse
Showing 20 of 40 trials
Page 1 / 2

Organizations

Research & Development (33)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit141332004
University of CopenhagenAcademic/Hospital4422009
Icahn School of Medicine at Mount SinaiAcademic/Hospital2222014
Peking UniversityAcademic/Hospital2212020
Centre Hospitalier Intercommunal CreteilAcademic/Hospital1112021
Duke UniversityAcademic/Hospital1112022
GlaxoSmithKlineFor profit1012002
Hospital KemamanAcademic/Hospital1112017
IQVIAFor profit1012014
Jaeb Center for Health ResearchAcademic/Hospital1112008
Mary Mediatrix Medical Center, Lipa City, PhilippinesAcademic/Hospital1012009
Mayo ClinicAcademic/Hospital1112022
National Heart, Lung, and Blood Institute (NHLBI)Government1012022
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012008
National Institutes of Health (NIH)Government1012022
Nishtar Medical UniversityAcademic/Hospital1012024
NovartisFor profit1112007
RESnTEC, Institute of ResearchAcademic/Hospital1112024
Stanford UniversityAcademic/Hospital1112003
Telemark Hospital TrustAcademic/Hospital1112006
33 organizations
Page 1 / 2

Marketing (19)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitMKTGJan 7, 2008
Ani PharmaceuticalsFor profitNDA2May 17, 1976
Ani PharmaceuticalsFor profitMKTGMay 17, 1976
Areva Med LLCFor profitMKTGNov 8, 2013
Athenex, Inc.For profitMKTGApr 23, 2004
Chartwell PharmaceuticalsFor profitMKTGApr 23, 2004
Dr. Reddy's LaboratoriesFor profitMKTGJul 20, 2004
Epic Pharma LlcFor profitMKTGJan 7, 2008
FreseniusFor profitMKTGMay 26, 2004
HikmaFor profitMKTGMay 20, 2009
Impax LaboratoriesFor profitMKTGJun 26, 2001
Lannett Company, Inc.For profitMKTGMar 25, 2005
NovartisFor profitNDA2
Pharmacare PLC, PalestineFor profitNDA2Nov 30, 1981
Sanofi-AventisFor profitNDA2Mar 25, 1974
Sanofi-AventisFor profitNDAMar 25, 1974
TWi Biotechnology, Inc.For profitMKTGJun 19, 2020
TevaFor profitMKTGJul 20, 2004
United BiomedicalFor profitMKTGNov 8, 2013